Support for Nucleic Acid-Based Approach in Developing Flu Vaccine Platforms

Funding News Edition: January 08, 2020
See more articles in this edition

NIAID aims to support research projects that develop preventive nucleic acid-based vaccine platforms to protect against seasonal or pandemic influenza. Ideally, these platforms will allow for flexible, nimble, large-scale production of vaccines that can also meet the rapid manufacturing requirements needed during an influenza pandemic.

As described in Notice of Special Interest (NOSI): Development of Nucleic Acid-Based Vaccines Against Seasonal and/or Pandemic Influenza, we encourage applicants to propose such research through the following funding opportunity announcements (FOAs):

Several candidate nucleic acid-based vaccines are already entering clinical trials, though NIAID remains interested in further preclinical development. NIAID will also consider nucleic acid-based vaccines that encode prophylactic monoclonal antibodies.

Should you apply in response to this NOSI, you must include “NOT-AI-20-017” (without quotation marks) in the Agency Routing Identifier field (box 4B) of the SF 424 R&R form. Otherwise, follow the due dates and other administrative requirements of the FOA through which you submit your application.

The first available due dates through this NOSI’s linked FOAs are February 5 for R01 applications, March 16 for R21 applications, and April 6 for small business applications. The NOSI will remain open through September 8, 2021.

If you have any questions, reach out to Dr. Jennifer Gordon, NIAID’s scientific contact for the NOSI.

Contact Us

Email us at for help navigating NIAID’s grant and contract policies and procedures.

Content last reviewed on